Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.68 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.68 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.68 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.68 |
| ▸ | F2 | P00734 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 3/20 | 0.66 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.63 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | IDE | P14735 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890035 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL12551869 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL21531161 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL25375533 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL19952819 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL24974563 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL24670280 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL24163378 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL21151130 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL13021124 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519384-B1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORP (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025243001-A1 | COVALENT TAG | UNIVERSITY OF DUNDEE (GB) | 2025-11-27 | — | — | WO | disclosed |
| EP-4615837-A1 | USEFUL COMPOUNDS FOR MODULATING INFLAMMATION | Flagship Pioneering Innovations VI, LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4519385-A2 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4519384-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | Promega Corporation (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240191211-A1 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION | 2024-06-13 | — | — | US | disclosed |
| WO-2024102901-A1 | USEFUL COMPOUNDS FOR MODULATING INFLAMMATION | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2023215497-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215514-A2 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2023-11-09 | — | — | US | disclosed |
| US-20230046947-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-02-16 | — | — | US | disclosed |
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| CN-110596365-B | Method and kit for determining cholesterol loading capacity of lipoprotein | 希森美康株式会社 | 2022-11-15 | — | — | CN | disclosed |
| US-11486875-B2 | Method for measuring cholesterol uptake capacity of lipoproteins | SYSMEX CORPORATION (JP) | 2022-11-01 | — | — | US | disclosed |
| EP-4069311-A1 | REACTIVE CONJUGATES | Debiopharm Research & Manufacturing SA (CH) | 2022-10-12 | — | — | EP | disclosed |
| EP-3623811-B1 | METHOD FOR MEASURING CHOLESTEROL UPTAKE CAPACITY OF LIPOPROTEINS | SYSMEX CORP (JP) | 2022-07-13 | — | — | EP | disclosed |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| EP-3076175-A1 | DETECTION AND QUANTIFICATION OF O-ACETYL-ADP-RIBOSE AS A READOUT SYSTEM FOR MEASURING THE ACTIVITY OF E.G. SIRTUINS | Boehringer Ingelheim International GmbH (DE) | 2016-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | BTD, HLCS, TYR | PRSS1 3477/4885PRSS2 3699/4885PRSS3 3560/4885 |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | PRSS1 1431/4885PRSS2 2036/4885PRSS3 1477/4885 |
| US-20230046947-A1 | REACTIVE CONJUGATES | FCGR3B, FCGR1A, FCGR2A | PRSS1 4208/4885PRSS2 4155/4885PRSS3 3661/4885 |
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | PRSS1 1694/4885PRSS2 2666/4885PRSS3 2347/4885 |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | PRSS1 1647/4885PRSS2 2229/4885PRSS3 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.